Fulcrum Working Capital vs Earnings before Tax Analysis
FULC Stock | USD 9.44 0.02 0.21% |
Trend analysis of Fulcrum Therapeutics balance sheet accounts such as Other Current Liabilities of 5.2 M or Total Current Liabilities of 15 M provides information on Fulcrum Therapeutics' total assets, liabilities, and equity, which is the actual value of Fulcrum Therapeutics to its prevalent stockholders. By breaking down trends over time using Fulcrum Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Fulcrum |
About Fulcrum Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Fulcrum Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Fulcrum Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Fulcrum Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Fulcrum currently owns. An asset can also be divided into two categories, current and non-current.
Fulcrum Therapeutics Balance Sheet Chart
Fulcrum Therapeutics Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Fulcrum Therapeutics uses and utilizes its capital. It also shows what exactly a company owns and owes.
At present, Fulcrum Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Property Plant And Equipment Net is expected to grow to about 16.6 M, whereas Total Assets are forecasted to decline to about 164.9 M. Add Fundamental
Total Assets
Total assets refers to the total amount of Fulcrum Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Fulcrum Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Fulcrum Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Fulcrum Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Fulcrum Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fulcrum Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.As of March 29, 2024, Selling General Administrative is expected to decline to about 25.3 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 113.7 M
2018 | 2019 | 2023 | 2024 (projected) | Interest Income | 518K | 1.5M | 1.7M | 1.8M | Net Interest Income | 518K | 1.5M | 1.7M | 1.8M |
Fulcrum Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Fulcrum Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fulcrum Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 110.4M | 129.6M | 235M | 226.7M | 257.7M | 164.9M | |
Other Current Liab | 5.9M | 7.7M | 74K | 9.6M | 8.7M | 5.2M | |
Total Current Liabilities | 12.1M | 26.7M | 19.2M | 16.7M | 13.7M | 15.0M | |
Total Stockholder Equity | 87.2M | 95.2M | 211.5M | 198.9M | 235.2M | 142.3M | |
Other Liab | 11.1M | 7.7M | 4.3M | 197K | 177.3K | 168.4K | |
Net Tangible Assets | 87.2M | 95.2M | 211.5M | 198.9M | 228.8M | 240.2M | |
Property Plant And Equipment Net | 87.9M | 8.4M | 7.4M | 16.0M | 12.4M | 16.6M | |
Net Debt | (96.7M) | (57.0M) | (35.4M) | (21.7M) | (14.7M) | (15.5M) | |
Retained Earnings | (150.8M) | (221.6M) | (302.5M) | (412.3M) | (509.7M) | (484.2M) | |
Accounts Payable | 2.2M | 4.1M | 4.8M | 3.6M | 2.8M | 3.2M | |
Cash | 96.7M | 57.1M | 35.4M | 35.1M | 25.6M | 36.9M | |
Non Current Assets Total | 10.4M | 16.7M | 9.0M | 19.2M | 15.5M | 13.4M | |
Non Currrent Assets Other | (78.7M) | 7.2M | 542K | 2.1M | 2.0M | 2.1M | |
Other Assets | 1.2M | 1.7M | 1.6M | 3.2M | 3.7M | 3.9M | |
Cash And Short Term Investments | 96.7M | 112.9M | 218.2M | 202.9M | 236.2M | 147.7M | |
Net Receivables | 111K | 2.7M | 4.1M | 1.1M | 2.2M | 1.7M | |
Common Stock Total Equity | 23K | 28K | 41K | 52K | 59.8K | 62.8K | |
Common Stock Shares Outstanding | 11.0M | 25.4M | 35.4M | 45.0M | 61.3M | 32.4M | |
Liabilities And Stockholders Equity | 110.4M | 129.6M | 235M | 226.7M | 257.7M | 164.9M | |
Non Current Liabilities Total | 11.1M | 7.7M | 4.3M | 11.0M | 8.8M | 7.7M | |
Capital Surpluse | 237.9M | 316.8M | 514.4M | 612.0M | 703.8M | 739.0M | |
Capital Lease Obligations | 46K | 50K | 17K | 13.4M | 10.8M | 11.4M | |
Inventory | 3.0M | (2.8M) | (473K) | (852K) | (766.8K) | (728.5K) | |
Other Current Assets | 284K | 74K | 4.2M | 4.4M | 3.7M | 2.1M | |
Other Stockholder Equity | 237.9M | 316.8M | 514.4M | 612.0M | 744.9M | 404.7M | |
Total Liab | 23.3M | 34.4M | 23.5M | 27.7M | 22.5M | 22.7M | |
Net Invested Capital | 87.2M | 95.2M | 211.5M | 198.9M | 235.2M | 136.8M | |
Property Plant And Equipment Gross | 9.2M | 8.4M | 7.4M | 6.9M | 25.2M | 26.4M | |
Total Current Assets | 100.1M | 112.9M | 226.0M | 207.5M | 242.2M | 151.5M | |
Accumulated Other Comprehensive Income | (110.4M) | (2K) | (397K) | (797K) | (136K) | (142.8K) | |
Non Current Liabilities Other | 150K | 55K | 3.1M | 197K | 226.6K | 215.2K | |
Net Working Capital | 87.9M | 92.8M | 206.8M | 190.8M | 228.5M | 137.5M | |
Short Term Debt | 50K | 17K | 9.6M | 2.6M | 2.2M | 2.3M | |
Common Stock | 23K | 28K | 41K | 52K | 62K | 35.0K | |
Property Plant Equipment | 9.2M | 8.4M | 7.4M | 6.9M | 7.9M | 8.3M | |
Short Long Term Debt Total | 50K | 17K | 469K | 13.4M | 10.8M | 11.4M | |
Current Deferred Revenue | 4.0M | 14.9M | 4.7M | 934K | 840.6K | 798.6K | |
Capital Stock | 23K | 28K | 41K | 52K | 62K | 40.7K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Fulcrum Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Fulcrum Therapeutics' short interest history, or implied volatility extrapolated from Fulcrum Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Global Correlations Find global opportunities by holding instruments from different markets | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Fulcrum Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.272 | Return On Assets (0.29) | Return On Equity (0.45) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.